Q1 Earnings Estimate for Vaxcyte Issued By Leerink Partnrs

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Vaxcyte in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn ($1.01) per share for the quarter. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.39) EPS, FY2025 earnings at ($4.77) EPS, FY2026 earnings at ($5.46) EPS, FY2027 earnings at ($5.84) EPS, FY2028 earnings at ($5.17) EPS and FY2029 earnings at $1.63 EPS.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14.

PCVX has been the topic of a number of other reports. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Guggenheim restated a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Trading Down 1.6 %

Shares of PCVX stock opened at $73.02 on Friday. The stock has a market capitalization of $9.10 billion, a P/E ratio of -15.87 and a beta of 0.98. The firm’s 50 day moving average is $84.59 and its 200 day moving average is $94.71. Vaxcyte has a 12 month low of $58.10 and a 12 month high of $121.06.

Institutional Trading of Vaxcyte

Institutional investors and hedge funds have recently made changes to their positions in the stock. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the 4th quarter valued at $28,000. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI purchased a new stake in shares of Vaxcyte during the 4th quarter valued at $41,000. Blue Trust Inc. grew its holdings in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the sale, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,180,820.35. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the sale, the chief executive officer now owns 450,301 shares in the company, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 76,616 shares of company stock worth $6,766,481 in the last three months. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.